Today's Date: June 9, 2023
Providing LGBTQI+ people with a safe home in Canada   •   Perfuze Announces Appointment of New Chair of the Board   •   Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematol   •   Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI C   •   BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congres   •   Children's Miracle Network Hospitals® Celebrates 40th Anniversary with Celebrity Friends and Supporters   •   A New Era of Three-Row Luxury: The First-Ever Lexus TX   •   SoftwareReviews Reveals the Top ESG Software Solutions That Enable Organizations to Build a Culture of Purpose and Sustainabilit   •   USCIB Releases Pride Month Statement, Supporting Equality and Inclusion   •   Hengtong Optic-Electric Releases 2022 ESG Report at the PT Expo   •   Ventas Realty, Limited Partnership Announces Upsize and Pricing of $750 Million of Exchangeable Senior Notes   •   Sophisticated Utility Vehicle: all-new 2024 Lexus GX Redefines SUV   •   Saudi Arabia: Modern means of transportation for easier Hajj   •   IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy   •   Fairmont Mayakoba to host exclusive 2023 pride celebration   •   Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presen   •   Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023   •   ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at   •   TIO EQUITY ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Tingo Group, Inc. Investors with Losses in Excess of $100K to Secur   •   CGTN: China stresses green development, ethnic unity in modernization drive
Bookmark and Share

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Prog

LONDON , March 20 /Businesswire/ - CHARM Therapeutics (“CHARM”), a 3D deep learning biotechnology company discovering and developing transformational medicines, today announced a strategic discovery collaboration with Bristol Myers Squibb (NYSE: BMY) for the identification and optimisation of compounds against Bristol Myers Squibb selected targets. CHARM will leverage DragonFold, its proprietary deep learning platform that identifies novel molecules through protein-ligand co-folding, to discover novel compounds.

“CHARM is excited to collaborate with Bristol Myers Squibb for the discovery of new potential medicines utilising our proprietary DragonFold platform. The CHARM team is looking forward to a productive collaboration,” said Laksh Aithani, co-founder and CEO of CHARM.

“We’re continually sourcing cutting-edge technologies that will help us accelerate our efforts to treat diseases where patients are suffering and new options are needed,” said Michael Ellis, Senior Vice President, Small Molecule Drug Discovery, Bristol Myers Squibb. “We look forward to leveraging CHARM’s insights in 3D deep learning to help shape how we discover and advance critical medicines, underscoring our mission of transforming patients’ lives through science.”

Under the terms of the agreement, CHARM is responsible for the early discovery of compounds against targets of interest to Bristol Myers Squibb, who has the option to license and develop compounds from the collaboration. In addition to an upfront payment and investment in CHARM, which provides significant additional operational runway, CHARM is eligible to receive additional payments should Bristol Myers Squibb exercise its option to any of the program compounds.

“Our collaboration helps validate the innovative potential of the DragonFold platform for rapidly advancing important small molecule discovery programs. We believe that DragonFold will enable the discovery of novel medicines against targets that have thus far proven to be intractable,” said Gary D. Glick, Ph.D., Executive Chair of CHARM.

About CHARM Therapeutics

CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines. Founded on 3D deep learning inspired by the breakthroughs of co-founder David Baker, CHARM Therapeutics has developed a proprietary technology based on the first rapid, accurate protein/ligand co-folding algorithm. The company’s goal is to use these insights to address challenging targets in cancer and other disease areas and discover and develop new drugs against these targets.

London-based CHARM Therapeutics has raised $50 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology. It is supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Axial and Braavos. For more information, please visit:

STORY TAGS: Software, Research, Professional Services, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Artificial Intelligence, Data Analytics, Science, Biotechnology, Health, Contract/Agreement, United Kingdom, Europe,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News